Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the manageme...
Main Author: | Yamini, Prashanth |
---|---|
Other Authors: | Dang Thuy Tram |
Format: | Final Year Project (FYP) |
Language: | English |
Published: |
Nanyang Technological University
2024
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/177425 |
Similar Items
-
Ethnopharmacological Survey of Medicinal Plants Used in the Management of Skin-Related Conditions in Ilorin, North-Central, Nigeria
by: Mansurat B. Falana, et al.
Published: (2022-10-01) -
Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022-10-01) -
East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease
by: Manju Sharma, et al.
Published: (2018-03-01) -
Psoriasis, chronic eczema and atopic dermatitis in males: functioning of sympathoadrenal and vagoinsular systems
by: N. Yu. Reznichenko
Published: (2016-10-01) -
Quality of Life and Cost of Illness in Patients with Hand Dermatitis: A Cross-sectional Study
by: Yerragangu Deepthi Chowdary, et al.
Published: (2023-06-01)